Myomo (MYO) to Release Earnings on Wednesday

Myomo (NYSEAMERICAN:MYO) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Myomo to post earnings of ($0.11) per share and revenue of $9.4380 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Myomo Stock Down 0.4%

Shares of NYSEAMERICAN MYO opened at $0.93 on Monday. Myomo has a 12 month low of $0.80 and a 12 month high of $7.17. The company has a current ratio of 2.39, a quick ratio of 2.03 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $35.00 million, a price-to-earnings ratio of -4.03 and a beta of 1.48. The business has a 50-day moving average of $1.00 and a 200-day moving average of $2.12.

Insider Buying and Selling

In other Myomo news, CEO Paul R. Gudonis purchased 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the purchase, the chief executive officer directly owned 1,259,013 shares of the company’s stock, valued at $1,196,062.35. The trade was a 4.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Thomas F. Kirk purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average cost of $1.15 per share, with a total value of $57,500.00. Following the purchase, the director directly owned 474,420 shares of the company’s stock, valued at $545,583. This trade represents a 11.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 150,000 shares of company stock valued at $160,000. Insiders own 4.54% of the company’s stock.

Institutional Trading of Myomo

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MYO. Invesco Ltd. purchased a new stake in Myomo in the second quarter worth $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Myomo in the second quarter worth $38,000. Engineers Gate Manager LP lifted its stake in Myomo by 62.8% in the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Myomo in the first quarter worth $75,000. Finally, New York State Common Retirement Fund purchased a new stake in Myomo in the second quarter worth $97,000. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MYO. HC Wainwright cut their price objective on Myomo from $9.50 to $5.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Ascendiant Capital Markets cut their target price on Myomo from $11.50 to $10.50 and set a “buy” rating for the company in a research note on Monday, September 22nd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $7.83.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.